Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangxue Qufeng Zhitong granules
- Development stage
- Unknown
- Lead developer
- 广东方盛健盟药业
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Yangxue Qufeng Zhitong granules (previously known as Nuolitong Granules during development) is a Class 1.1 innovative traditional Chinese medicine (TCM) developed by Hunan Fangsheng Pharmaceutical through its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical. The formulation is a multi-herb TCM preparation composed of Astragali Radix, Angelicae Sinensis Radix, Codonopsis Radix, bran-fried Atractylodis Macrocephalae Rhizoma, Chuanxiong Rhizoma, Saposhnikoviae Radix, Cimicifugae Rhizoma, Bupleuri Radix, Menthae Haplocalycis Herba, Schizonepetae Herba, Notopterygii Rhizoma et Radix, and Angelicae Dahuricae Radix. It is developed by modifying Zhang Xichun's Shengxian Decoction. The drug is indicated for the treatment of frequent episodic tension-type headache, which TCM classes as Qi and Blood Deficiency Syndrome. It was approved for marketing in China in June 2025 and added to China's National Reimbursement Drug List in December 2025.
- Other names
- NuolitongNuolitong GranuleNuolitong GranulesYangxue Qufeng Zhitong GranuleYangxue Qufeng Zhitong Granules养血祛风止痛颗粒诺丽通颗粒
Beyond the preview
Go deeper on Yangxue Qufeng Zhitong granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yangxue Qufeng Zhitong granules.